Cameron J Smith
Overview
Explore the profile of Cameron J Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith C, Eavis H, Briggs C, Henrici R, Karpiyevich M, Ansbro M, et al.
J Biol Chem
. 2025 Feb;
301(3):108266.
PMID: 39909372
Deubiquitinating enzymes function to cleave ubiquitin (Ub) moieties from modified proteins, serving to maintain the pool of free Ub in the cell while simultaneously impacting the fate and function of...
2.
3.
Wang D, Zhuo Y, Karfunkle M, Patil S, Smith C, Keire D, et al.
Molecules
. 2021 Jul;
26(14).
PMID: 34299526
Peptide and protein drug molecules fold into higher order structures (HOS) in formulation and these folded structures are often critical for drug efficacy and safety. Generic or biosimilar drug products...
4.
Wang D, Park J, Patil S, Smith C, Leazer Jr J, Keire D, et al.
J Pharm Sci
. 2020 Jan;
109(4):1519-1528.
PMID: 31927041
Protein or peptide higher order structure (HOS) is a quality attribute that could affect therapeutic efficacy and safety. Where appropriate, the HOS similarity between a proposed follow-on product and the...
5.
Weissman K, Smith C, Hanefeld U, Aggarwal R, Bycroft M, Staunton J, et al.
Angew Chem Int Ed Engl
. 2018 May;
37(10):1437-1440.
PMID: 29710889
The production of genetically engineered polyketides depends critically on thioesterase activity for product release. In vitro studies with the thioesterase from the erythromycin polyketide synthase (PKS) have demonstrated that the...
6.
Meng D, Andre P, Bateman T, Berger R, Chen Y, Desai K, et al.
Bioorg Med Chem Lett
. 2015 Aug;
25(22):5437-43.
PMID: 26318999
Using structure based drug design, a novel class of potent coagulation factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds were evaluated...
7.
Zhang T, Andre P, Bateman T, Chen Y, Desai K, Ellsworth K, et al.
Bioorg Med Chem Lett
. 2015 May;
25(21):4945-4949.
PMID: 25978966
Using structure based drug design (SBDD), a novel class of potent coagulation Factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds demonstrated...
8.
Smith C, Ali A, Hammond M, Li H, Lu Z, Napolitano J, et al.
J Med Chem
. 2011 Jun;
54(13):4880-95.
PMID: 21682257
The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically,...
9.
Kallashi F, Kim D, Kowalchick J, Park Y, Hunt J, Ali A, et al.
Bioorg Med Chem Lett
. 2010 Nov;
21(1):558-61.
PMID: 21094047
We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy...
10.
Smith C, Ali A, Chen L, Hammond M, Anderson M, Chen Y, et al.
Bioorg Med Chem Lett
. 2009 Nov;
20(1):346-9.
PMID: 19914065
A series of 2-arylbenzoxazole inhibitors of the cholesterol ester transfer protein (CETP) is described. Structure-activity studies focused on variation of the substitution of the benzoxazole moiety. Substitution at the 5-...